22nd Century Group (XXII) to Release Quarterly Earnings on Thursday

22nd Century Group (NASDAQ:XXII) is set to announce its earnings results on Thursday, March 7th.

22nd Century Group Stock Up 0.7 %

Shares of 22nd Century Group stock traded up $0.00 during midday trading on Wednesday, hitting $0.16. The company’s stock had a trading volume of 513,542 shares, compared to its average volume of 1,246,188. 22nd Century Group has a 1-year low of $0.13 and a 1-year high of $14.25. The company has a quick ratio of 0.62, a current ratio of 1.02 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $5.00 million, a P/E ratio of -0.02 and a beta of 1.54. The stock has a 50-day simple moving average of $0.17 and a 200-day simple moving average of $0.52.

Hedge Funds Weigh In On 22nd Century Group

Several institutional investors and hedge funds have recently bought and sold shares of XXII. Vanguard Group Inc. grew its stake in shares of 22nd Century Group by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 10,457,121 shares of the biotechnology company’s stock valued at $9,696,000 after buying an additional 1,615,666 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of 22nd Century Group in the third quarter valued at about $1,418,000. Renaissance Technologies LLC bought a new position in 22nd Century Group in the 2nd quarter worth approximately $463,000. HighTower Advisors LLC lifted its holdings in shares of 22nd Century Group by 29.2% during the first quarter. HighTower Advisors LLC now owns 1,543,656 shares of the biotechnology company’s stock worth $1,187,000 after buying an additional 348,500 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in 22nd Century Group during the second quarter worth $133,000.

22nd Century Group Company Profile

22nd Century Group, Inc, an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies.